StreetAlpha.app
Home › Stocks › REPL

Replimune Group, Inc. (REPL)

Healthcare
$19.07
▼ −0.83%
LAST CLOSE · NOV 20

Replimune develops oncolytic immunotherapies, treatments built on engineered viruses that target skin cancers. It last closed at $19.07 on Nov 20, down 0.83% on the day. The next earnings report for REPL is expected around Tue, Feb 2, 2027. For the quarter ended Sep 2026, REPL reported EPS of -$0.54. Over its last 8 reports the stock moved an average of 5.8% the session after earnings. Over the last 12 months REPL insiders bought $0 of stock on the open market and sold $4.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is REPL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold REPL.

Key Stats

Last 12 months
Results
Net income
−$271.0M
EPS (diluted)
−$2.79
Free cash flow
−$245.8M
Valuation
Market cap
$1.8B
94.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$307.8M
At Sep 30
Debt
$99.8M
At Sep 30
Shareholder equity
$204.8M
Shares outstanding
94.8M
At Oct 23
Fiscal year endsMarch
ExchangeNasdaq
Financials history
FY2022: −$118.0M−$118.0MFY2022FY2023: −$174.3M−$174.3MFY2023FY2024: −$215.8M−$215.8MFY2024FY2025: −$247.3M−$247.3MFY2025FY2026: −$313.9M−$313.9MFY2026

From REPL's SEC filings, latest 10-Q/A for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Next report
Feb 2
Estimated date · Time not announced
Reported EPS
-$0.54
Quarter ended Sep 2026
Year ago EPS
-$0.90
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.79Dec '24Mar 2025: -$0.82Mar '25Jun 2025: -$0.95Jun '25Sep 2025: -$0.90Sep '25Dec 2025: -$0.77Dec '25Mar 2026: -$0.76Mar '26Jun 2026: -$0.72Jun '26Sep 2026: -$0.54Sep '26Latest -$0.54
Revenue by quarter
Not enough quarters on file yet.
How REPL moved after its last 8 reports
Average move the session after a report ±5.8%
Oct 28, 2026Time not announced+23.1%
Aug 14, 2026Time not announced−1.4%
Jun 29, 2026Time not announced−3.7%
Feb 3, 2026Time not announced+5.8%
Nov 6, 2025Time not announced−0.9%
Aug 7, 2025Time not announced−0.4%
May 22, 2025Time not announced+3.5%
Feb 12, 2025Time not announced+7.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on REPLStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on REPL
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on REPL

Technical Analysis

REPL · as of the Nov 20 close · updated each morning
Uptrend

The stock sits between its 20 and 50 day averages. It is 46% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 54). The nearest support is the Pivot S1 at $18.67, and the nearest resistance the Pivot at $19.09.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.7%/day
Key levels
$23.5452 week high+23.4%
$23.54Swing high (Nov 11)+23.4%
$19.48Pivot R1+2.1%
$19.4720 day average+2.1%
$19.09Pivot+0.1%
$19.07Last close
$18.67Pivot S1−2.1%
$15.3450 day average−19.6%
$14.90Swing low (Aug 31)−21.9%
$13.95100 day average−26.8%
$10.32200 day average−45.9%
$1.5052 week low−92.1%
Indicators
RSI (14)54.26Middle of its rangeNeutral
MACD1.53Below its signal lineBearish
Stochastic26.8Middle of its rangeNeutral
ADX (14)36.2Trending up
Williams %R-92.2Oversold below −80, overbought above −20Oversold
CCI (20)-7.6Oversold below −100, overbought above 100Neutral
Rate of change−11.8%Change over 10 sessionsBearish
ATR (14)$1.27Typical daily range, 6.7% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for REPL

What happened before

See how REPL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow REPL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How REPL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for REPLHow many large options trades hit REPL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

REPL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●116 buying vs 104 selling
  • ▲Held by funds +11.3 pts
  • ▲Funds holding +8
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding211203+3.9%
In funds' top 10330.0%
Held by funds112.1%100.8%+11.3 pts
New / increased49 / 6775 / 71−20.5%
Reduced / sold out62 / 4245 / 54+5.1%
Put/call ratio0.050.33−85.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See REPL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

REPL Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$4.1M21 sales · 8 insiders
7% of the selling was under pre-arranged trading plans.
2025-12 sold $144K2026-04 sold $52K2026-05 sold $474K2026-06 sold $111K2026-08 sold $1.0M2026-11 sold $2.3MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Emily Luisa HillCFOSale14,709$21.60$318K
Nov 16Sushil PatelCEOSale49,026$21.60$1.1M
Nov 16Andrew SchwendenmanChief Accounting OfficerSale2,148$21.60$46K
Nov 16Konstantinos XynosChief Medical OfficerSale16,198$21.60$350K
Nov 9Joseph P SlatteryDirectorSale5,200$21.80$113K
Nov 2Kapil DhingraDirectorSale21,500$19.00$409K
Every insider buy and sale for REPL over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See REPL insider trades →

From SEC Form 4 filings by REPL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether REPL is in one of them and how their past REPL trades turned out.

REPL in the AI portfolios
Loading…

REPL News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered REPL in an article yet. Here's the latest on the wider market.

REPL in the news

About Replimune Group

Replimune is a biotechnology company based in Woburn, Massachusetts, that develops oncolytic immunotherapies for cancer. These treatments use an engineered herpes simplex virus to kill tumor cells directly and to stimulate the immune system against the cancer. Its lead candidate, RP1, is being studied mainly in advanced melanoma and other skin cancers, with patients as the intended users. The company's products are still in clinical development and are not yet sold.

Headquarters
Woburn, MA